Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of cystic fibrosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of cystic fibrosis for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cystic fibrosis patient populations covering 171 countries and more…

In 2019, sales of branded biologics for respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029…

Clarivate Epidemiology’s coverage of respiratory syncytial virus (RSV) infection comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United…

Allergic respiratory disorders—such as allergic rhinitis, chronic rhinosinusitis, and nasal polyps—are characterized by activation of inflammatory pathways and the production of immunoglobulin…

ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening…

Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…

Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…

The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for…

Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder and the third-leading cause of death in the United States. No currently available therapy treats the underlying cause of…